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Abstract Despite recent advances in the management of
patients with heart failure, morbidity and mortality rates
remain high. Common causes of heart failure are ischae-
mic heart disease, uncontrolled hypertension and valvular
disease. However, in up to 50 % of the cases its exact
cause remains initially unknown; this condition is called
idiopathic dilated cardiomyopathy (DCM). Improved di-
agnostic methods, most notably the advancements in
molecular and immunohistological biopsy techniques
and genetic research, have endorsed a new era in the
diagnosis and classification of patients with idiopathic
DCM. These insights have led to novel aetiology-based
treatment strategies and improved outcome. The present
article will briefly discuss all causes of DCM with a
special focus on inflammatory- and virus-mediated forms
of DCM.
Keywords Idiopathic dilated cardiomyopathy .
Possible triggers . Viral-mediated . Inflammatory mediated .
Treatment strategies
Introduction
Despite recent advances in the management of patients
with heart failure, morbidity and mortality rates remain
high. It is the only cardiovascular disease that has in-
creased in prevalence over the last 20 years [1]. With
over 200,000 patients suffering from heart failure in the
Netherlands, it continues to impose a great burden on the
health care system. Common causes of heart failure are
ischaemic heart disease, uncontrolled hypertension and
valvular disease. However, in up to 50 % of the cases
its exact cause remains initially unknown; this condition
is called idiopathic dilated cardiomyopathy (DCM) [2].
Patients with idiopathic DCM are relatively young, ranging
between 20 and 60 years, and often still in the prime of their
lives. To discriminate different aetiologies of DCM, specific
diagnostic methods including serummarkers, cardiac biopsies
and genetic screening are crucial to improve care and outcome
in these patients.
Triggers of idiopathic dilated cardiomyopathy
DCM may be the consequence of a wide variety of causes,
including virus-mediated disease, immune dysregulation,
toxic and metabolic, inherited, and tachycardia-induced
conditions (Fig. 1) [2, 3]. We will briefly discuss all
the possible triggers of DCM with a special focus on
inflammatory- and virus-mediated forms of DCM.
Toxic and metabolic triggers
Toxic cardiomyopathy results from toxic exposure of a
variety of cardiotoxic agents, most notably alcohol and
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chemotherapeutic drugs. Metabolic cardiomyopathies can
be caused by a wide spectrum of pathological metabolic
conditions (Table 1) [4].
Tachycardia-induced cardiomyopathy
Tachycardia-induced cardiomyopathy (TIC) is caused by
sustained rapid ventricular rates and is one of the well-
known forms of reversible myocardial diseases after the
normalisation of heart rate. It may follow any type of
chronic cardiac arrhythmia: supraventricular tachyar-
rhythmias, ventricular tachycardia, and frequent prema-
ture ventricular complexes. The diagnosis of TIC remains
difficult since cardiomyopathy and tachycardia are often
identified simultaneously [5]. In up to 70 % of the cases,
a tachycardia is the symptom and not the cause of an
underlying cardiomyopathy.
Inherited triggers
A gene mutation may be the cause of DCM in up to 30 % of
the cases [3], therefore cardiogenetic screening is crucial in
idiopathic DCM patients. The most common mode of
inheritance is autosomal dominant transmission, al-
though less common forms including X-linked, autoso-
mal recessive and mitochondrial inheritance have also
been described. So far, 40 genes have been described
underlying inherited forms of idiopathic DCM. The
mutated genes predominantly encode two major sub-
groups: cytoskeletal and sarcomeric proteins. The cyto-
skeletal proteins include dystrophin, desmin, lamin A/C,
δ-sarcoglycan, β-sarcoglycan and metavinculin. In case of the
sarcomeric proteins they include β-myosin heavy chain,
myosin-binding protein C, actin, α-tropomyosin, and cardiac
troponin T and C. Furthermore, phospholamban, tafazzin and
the sodium-channel gene SCN5A have also been reported [3].
With the upcoming awareness of the importance of a
patient’s genetic background and the increasing numbers
of mutated genes found, genetic testing for idiopathic
DCM is becoming more common in clinical practice. In
turn, this is an opportunity to unravel the molecular com-
plexity of inherited DCM and develop possible disease-
modifying therapies in the future.
Virus infection
Virus infection may cause acute and chronic myocardi-
tis, and viral persistence has been linked to the devel-
opment of ‘idiopathic’ DCM. Until the 1990s, the most
frequently reported viruses in patients in the developed
countries were adenoviruses and enteroviruses. Recently,
parvovirus B19 (B19V) and human herpes virus-6 are
increasingly found in a significant percentage of patients
diagnosed with both acute and chronic cardiomyopathy.
While up to 50 % of young adults and up to 90 % of
the elderly have been infected with these cardiotropic
viruses, only an ‘unlucky few’ develop cardiac sequelae
[6].
Endomyocardial biopsies (EMB) are the golden stan-
dard for the diagnosis of virus presence and inflammation
in the heart. In the acute phase the living virus actively
Fig. 1 Possible triggers of idiopathic dilated cardiomyopathy
Table 1 Classification of toxic
and metabolic cardiomyopathies Infiltrative Amyloidosis (primary, familial autosomal dominant, senile, secondary forms)
Gaucher disease, Hurler’s disease and Hunter’s disease
Storage Haemochromatosis, Anderson-Fabry disease, glycogen storage disease (Pompe),
Niemann-Pick disease
Nutritional deficiencies Beriberi (thiamine), pellagra, scurvy, selenium, carnitine, nutritional disorder
such as kwasiorkor
Endocrine Diabetes mellitus, hyperthyroidism, hypothyriodism, hyperparathyroidism,
pheochromocytoma
Toxicity Alcohol, drugs (cocaine, catecholamines, lithium, phenothiazines, methysergide),
heavy metals (cobalt, lead, arsenic) and chemical agents
Consequence of cancer
therapy
Anthracyclines (doxorubicin, daunorubicin), cyclophosphamide and radiation
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replicates within the myocardium, causing damage to car-
diomyocytes and endothelial cells, in turn triggering the
innate immune response. In most patients, this leads to
viral clearance with subsequent adequate downregulation
of the immune response resulting in a healthy recovered
heart. However, in some patients the immune response is
insufficient and clearance of the virus is not achieved.
This may lead to viral persistence, causing progressive
myocyte damage which may ultimately progress to biven-
tricular dilatation with cardiac failure [6]. Therefore, a
certain genetic background appears to be a prerequisite
to developing clinical symptoms of myocarditis and/or
progression to virus-induced DCM. This is illustrated by
viral proteases which may cleave dystrophin, a cytosolic
protein which is also affected in patients with Duchenne
muscular dystrophy, leading to progression of heart failure
symptoms in these patients.
Immunological triggers
The role of viral infections in autoimmune disease has been
a topic of interest for over a century. There are two general
mechanisms by which viruses may induce autoimmunity.
Firstly, by providing or presenting the disease-initiating
antigen inducing the innate immune response, and secondly
by direct myocardial involvement of immune-mediated
inflammatory damage.
While viral clearance by the innate immune response
may improve clinical outcome, detrimental secondary
effects may be triggered after the primary infection.
Primed T-cells detect viral antigens and destroy infected
cardiomyocytes through Fas/Fas ligand, TNF-alpha, cy-
tokine and perforin pathways. In addition, some host
myocardial cellular antigens may share epitopic similar-
ities (molecular mimicry) with viral antigens, and may
therefore induce an autoimmune response that can sus-
tain the inflammatory response even after initial viral
elimination. This autoimmune response induces a chronic
inflammatory phase leading to immune-mediated myocyte
damage.
Secondly, besides a primary virus trigger for immune
dysregulation, also organ-specific and systemic immune-
mediated diseases such as Wegener granulomatosis,
Churg-Strauss syndrome or sarcoidosis are known to directly
affect the heart. Cardiac involvement is one of the
complications that substantially contribute to mortality
and morbidity in patients with systemic inflammatory
diseases. In addition, increased serum markers for im-
mune activation and autoantibodies (i.e. α/β-myosin
heavy chain, myosin light chain, troponin) may be
detected in patients with autoimmune-mediated inflam-
matory disease [7]. General screening for this immune
dysregulation with subsequent increased serum markers
is performed by measuring atrial natriuretic factor, sol-
uble interleukin-2 and neopterin levels.
Treatment strategies for idiopathic DCM
The goals of treatment in patients with idiopathic DCM
are to improve survival, slow disease progression, min-
imise risk factors, and alleviate symptoms. A standard
heart failure regimen with lifestyle modifications should
be initiated in all patients with this cardiac disease,
including ACE inhibitors, angiotensin-II receptor antag-
onists, beta-blockers, diuretics, aldosterone antagonists,
and digitalis. In some select patients known with
rhythm disturbances and/or increased risk of sudden
cardiac death, resynchronisation therapy combined with
an implantable cardioverter device should be considered
to reduce morbidity and mortality.
Besides standard heart failure therapy, determination of
the aetiology of idiopathic DCM is essential to initiate
treatment strategies if possible. In some cases, the specific
condition can be addressed, such as alcohol abuse and
chemotherapy, to prevent disease progression. Catheter
ablation should be considered in idiopathic DCM patients
with frequent monomorphic PVCs (>10 % of QRS com-
plexes), sustained rapid supraventricular tachyarrhythmias
or ventricular tachycardias.
In case of a previously unknown inflammatory heart
disease, distinction between virus-positive and virus-
negative inflammatory DCM, performed with EMB, is
crucial. Currently, sparse studies have investigated the role
of antiviral therapy in an inflammatory DCM with viral
presence. Recently, a pilot study with high-dose intravenous
immunoglobulin (2 g/kg), known to especially eliminate the
most frequently found B19V in cardiac biopsies, has dem-
onstrated favourable effects on both cardiac function as well
as virus elimination in virus-positive inflammatory DCM
patients [8]. Therefore, a randomised, double-blind, placebo-
controlled study has been initiated in patients with unex-
plained heart failure related to a significant B19V myocardial
persistence (>200 copies/μg DNA).
In the case of virus-negative inflammatory DCM
patients, a randomised controlled trial has recently dem-
onstrated the beneficial effects of immunosuppressive
therapy on myocardial function [9]. Patients received
either prednisone and aziathioprine for 6 months (43
patients) or placebo (42 patients) in addition to conven-
tional heart failure therapy for 6 months. Although other
studies have also investigated the effects of immunosup-
pression in autoimmune-mediated inflammatory DCM
(diagnosed by human leucocyte antigens or circulation auto-
antibodies), only Frustaci et al. confirmed the absence of
cardiotropic viruses in endomyocardial biopsies within his
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study population. Additionally, immunoadsorption therapy
with subsequent immunoglobulin substitution has proven to
be an effective immunomodulatory regimen in inflammatory
DCM patients, although the presence of myocardial virus
genome was also not addressed in these trials [10].
In conclusion, a detailed diagnosis of virus presence, inflam-
mation, autoimmune dysregulation and genetic background is
needed in idiopathic DCM patients to develop better classifi-
cation methods, more aetiology-based treatment strategies and
sophisticated prognostic models in the near future.
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